Tumor immunotherapy in melanoma: Strategies for overcoming mechanisms of resistance and escape

American Journal of Clinical Dermatology

Volumn 9, Issue 5, 2008, Pages 307-311

  Zigler, Maya ^a   Villares, Gabriel J ^a   Lev, Dina C ^a   Melnikova, Vladislava O ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti interleukin 8 monoclonal antibody, therapeutic use; Dacarbazine, therapeutic use; Malignant melanoma, treatment; Monoclonal antibodies, therapeutic use; Research and development

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CD146 ANTIGEN; CD31 ANTIGEN; CELL ADHESION MOLECULE; DACARBAZINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; MATRIX METALLOPROTEINASE; MELANOMA CELL ADHESION MOLECULE MONOCLONAL ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ABX INTERLEUKIN 8; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; RAF PROTEIN; SORAFENIB; TRANSCRIPTION FACTOR AP 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ADHESION; CYTOKINE RELEASE; CYTOTOXICITY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ACCUMULATION; DRUG TRANSPORT; ENDOTHELIUM CELL; HUMAN; IN VIVO STUDY; MELANOMA; MELANOMA CELL; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD146; ANTINEOPLASTIC AGENTS; DACARBAZINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-8; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS;

EID: 50049089470     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200809050-00004     Document Type: Review

References (46)

1. Bevona C, Sober AJ. Melanoma incidence trends. Dermatol Clin 2002; 20 (4): 589-95, vii
2. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93 (11): 824-42
3. Johnson TM, Yahanda AM, Chang AE, et al. Advances in melanoma therapy. J Am Acad Dermatol 1998; 38 (5 Pt 1): 731-41
4. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325 (3): 171-82
5. Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol 2001; 2 (3): 193-202
6. Becker JC, Kampgen E, Brocker E. Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 2000; 25 (6): 503-8
7. Cassel WA, Olkowski ZL, Murray DR. Immunotherapy in malignant melanoma [letter]. J Clin Oncol 1999; 17 (6): 1963
8. Crosby T, Fish R, Coles B, et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000; (2): CD001215
9. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001; 20 (1-2): 3-11
10. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17 (9): 2745-51
11. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18 (1): 158-66
12. Middleton MR, Lorigan P, Owen J, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82 (6): 1158-62
13. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006; 12 (7 Pt 2): 2353s-8s
14. Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 2006; 12 (7 Pt 2): 2331s-6s
15. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 2006; 12 (7 Pt 2): 2337s-41s
16. Leslie MC, Bar-Eli M. Regulation of gene expression in melanoma: new approaches for treatment. J Cell Biochem 2005; 94 (1): 25-38
17. Schadendorf D, Moller A, Algermissen B, et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151 (5): 2667-75
18. Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 1989; 86 (24): 9891-5
19. Koon HB, Atkins MB. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance. Expert Rev Anticancer Ther 2007; 7 (1): 79-88
20. La Porta CA. Drug resistance in melanoma: new perspectives. Curr Med Chem 2007; 14 (4): 387-91
21. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353 (20): 2135-47
22. von Gise A, Lorenz P, Wellbrock C, et al. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 2001; 21 (7): 2324-36
23. Röckmann H, Schadendorf D. Drug resistance in human melanoma: mechanisms and therapeutic opportunities. Onkologie 2003; 26 (6): 581-7
24. Lev DC, Ruiz M, Mills L, et al. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003; 2 (8): 753-63
25. Lev DC, Onn A, Melinkova VO, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004; 22 (11): 2092-100
26. Ball NJ, Yohn JJ, Morelli JG, et al. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994; 102 (3): 285-90
27. Hazan RB, Kang L, Roe S, et al. Vinculin is associated with the E-cadherin adhesion complex. J Biol Chem 1997; 272 (51): 32448-53
28. Jafari M, Papp T, Kirchner S, et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol 1995; 121 (1): 23-30
29. Satyamoorthy K, Li G, Gerrero MR, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003; 63 (4): 756-9
30. Okano J, Rustgi AK. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 2001; 276 (22): 19555-64
31. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007; 109 (3): 455-64
32. Kunz M, Goebeler M, Brocker EB, et al. IL-8 mRNA expression in primary malignant melanoma mRNA in situ hybridization: sensitivity, specificity, and evaluation of data. J Pathol 2000; 192 (3): 413-5
33. Nurnberg W, Tobias D, Otto F, et al. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 1999; 189 (4): 546-51
34. Singh RK, Gutman M, Radinsky R, et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54 (12): 3242-7
35. Singh RK, Gutman M, Reich R, et al. Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res 1995; 55 (16): 3669-74
36. Singh RK, Varney ML, Bucana CD, et al. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 1999; 9 (4): 383-7
37. Scheibenbogen C, Mohler T, Haefele J, et al. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995; 5 (3): 179-81
38. Ugurel S, Rappl G, Tilgen W, et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19 (2): 577-83
39. Luca M, Huang S, Gershenwald JE, et al. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151 (4): 1105-13
40. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17 (7): 4015-23
41. Huang S, Mills L, Mian B, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002; 161 (1): 125-34
42. Xie S, Luca M, Huang S, et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997; 57 (11): 2295-303
43. Shih IM, Speicher D, Hsu MY, et al. Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res 1997; 57 (17): 3835-40
44. Anfosso F, Bardin N, Frances V, et al. Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK). J Biol Chem 1998; 273 (41): 26852-6
45. Satyamoorthy K, Muyrers J, Meier F, et al. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene 2001; 20 (34): 4676-84
46. Mills L, Tellez C, Huang S, et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002; 62 (17): 5106-14